Exopharm Ltd Is A Clinical Stage Biopharmaceutical Company Based In Melbourneaustraliaspecializing In Extracellular Vesicleevbased Therapeutics And Drug Delivery Technologiesfounded In 2013 And Publicly Listed On The Australian Stock Exchange In 2016Exopharm Focuses On Developing Innovative Medicines That Utilize Evs To Facilitate Intercellular Communication And Deliver Therapeutic Payloads To Targeted Cells And Organs The Company Employs Its Proprietary Leap Technology For Large Scale Production Of High Purity Evs And Offers Advanced Engineering For Ev Customization To Optimize Delivery For Specific Applicationsexopharm Collaborates With Biopharmaceutical Firms To Enhance The Delivery Efficiency Of Their Drug Candidatesits Pipeline Includes Ev Based Therapeutics Aimed At Regenerative Medicine And Gene Therapywith Applications In Tissue Repair And Genetic Disease Treatmentin November 2022Exopharm Partnered With Sartorius Bia Separations To Improve Purification Processes For Exosome Productionfurther Supporting Its Commitment To Advancing Ev Manufacturing
